PDCD1 and chronic otitis media: This may be attributed to the high infiltration of T lymphocytes in the tumor microenvironment, potentially enhancing the immunotherapeutic efficacy of PD‐1 inhibitors in TBSCC that have undergone malignant transformation due to long‐standing chronic otitis media.